| Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan. |
businesswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates |
Arcellx, Inc. (ACLX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2025-05-08 22:10:41 |
Czytaj oryginał (ang.) |
| Baron Health Care Fund Q1 2025 Top Net Purchases And Sales |
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. |
seekingalpha.com |
2025-04-29 15:45:00 |
Czytaj oryginał (ang.) |
| Baron Health Care Fund Q1 2025 Top Contributors And Detractors |
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts. |
seekingalpha.com |
2025-04-29 15:30:00 |
Czytaj oryginał (ang.) |
| Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare. |
businesswire.com |
2025-03-20 18:00:00 |
Czytaj oryginał (ang.) |
| Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month |
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. |
globenewswire.com |
2025-03-18 10:44:00 |
Czytaj oryginał (ang.) |
| Arcellx Impressive Safety Data Leaves Doubts |
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story. |
seekingalpha.com |
2025-03-17 13:27:43 |
Czytaj oryginał (ang.) |
| Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates |
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to earnings of $0.42 per share a year ago. |
zacks.com |
2025-02-27 22:05:21 |
Czytaj oryginał (ang.) |
| Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s. |
businesswire.com |
2025-02-26 18:00:00 |
Czytaj oryginał (ang.) |
| 5 Biotech Breakthrough Stocks to Watch in 2025 |
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services. |
zacks.com |
2024-12-23 12:40:34 |
Czytaj oryginał (ang.) |
| Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. |
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. |
investors.com |
2024-12-09 12:50:35 |
Czytaj oryginał (ang.) |
| Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients |
On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM). |
benzinga.com |
2024-12-09 09:50:13 |
Czytaj oryginał (ang.) |
| Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of. |
businesswire.com |
2024-12-09 01:00:00 |
Czytaj oryginał (ang.) |
| Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice |
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-11-13 15:06:11 |
Czytaj oryginał (ang.) |
| Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? |
Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year. |
zacks.com |
2024-11-08 12:46:48 |
Czytaj oryginał (ang.) |
| Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates |
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. |
zacks.com |
2024-11-07 20:15:29 |
Czytaj oryginał (ang.) |
| Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? |
Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-11-07 09:31:12 |
Czytaj oryginał (ang.) |
| Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma |
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. |
seekingalpha.com |
2024-09-10 12:30:00 |
Czytaj oryginał (ang.) |
| Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates |
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago. |
zacks.com |
2024-08-08 22:25:34 |
Czytaj oryginał (ang.) |
| FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals |
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market. |
investorplace.com |
2024-07-04 18:13:23 |
Czytaj oryginał (ang.) |